Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Discovery of pyrazoles as novel FPR1 antagonists.

Morley AD, Cook A, King S, Roberts B, Lever S, Weaver R, Macdonald C, Unitt J, Fagura M, Phillips T, Lewis R, Wenlock M.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6456-60. doi: 10.1016/j.bmcl.2011.08.085. Epub 2011 Sep 6.

PMID:
21955939
2.

Lead optimisation of pyrazoles as novel FPR1 antagonists.

Morley AD, King S, Roberts B, Lever S, Teobald B, Fisher A, Cook T, Parker B, Wenlock M, Phillips C, Grime K.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):532-6. doi: 10.1016/j.bmcl.2011.10.090. Epub 2011 Nov 4.

PMID:
22094028
3.

Discovery of small molecule human FPR1 receptor antagonists.

Unitt J, Fagura M, Phillips T, King S, Perry M, Morley A, MacDonald C, Weaver R, Christie J, Barber S, Mohammed R, Paul M, Cook A, Baxter A.

Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7. doi: 10.1016/j.bmcl.2011.03.049. Epub 2011 Mar 21.

PMID:
21486695
4.

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.

Hoveyda HR, Roy MO, Blanc S, Noël S, Salvino JM, Ator MA, Fraser G.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):1991-6. doi: 10.1016/j.bmcl.2011.02.033. Epub 2011 Feb 13. Erratum in: Bioorg Med Chem Lett. 2011 Dec 1;21(23):7228.

PMID:
21376585
5.

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Brotherton-Pleiss CE, Dillon MP, Ford AP, Gever JR, Carter DS, Gleason SK, Lin CJ, Moore AG, Thompson AW, Villa M, Zhai Y.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1031-6. doi: 10.1016/j.bmcl.2009.12.044. Epub 2009 Dec 16.

PMID:
20045645
6.

Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT.

Int Immunopharmacol. 2016 Aug;37:43-58. doi: 10.1016/j.intimp.2015.08.036. Epub 2015 Sep 15. Review.

PMID:
26382576
7.

Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Cheng N, Ye RD, Quinn MT.

Biochem Pharmacol. 2014 Dec 15;92(4):627-41. doi: 10.1016/j.bcp.2014.09.027. Epub 2014 Oct 17.

8.

1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors.

Bruno O, Brullo C, Bondavalli F, Schenone S, Spisani S, Falzarano MS, Varani K, Barocelli E, Ballabeni V, Giorgio C, Tognolini M.

Bioorg Med Chem. 2009 May 1;17(9):3379-87. doi: 10.1016/j.bmc.2009.03.035. Epub 2009 Mar 25.

PMID:
19362486
9.

Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.

Zhang X, Song F, Kuo GH, Xiang A, Gibbs AC, Abad MC, Sun W, Kuo LC, Sui Z.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4762-7. doi: 10.1016/j.bmcl.2011.06.067. Epub 2011 Jun 29.

PMID:
21767952
10.

Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library.

Forsman H, Kalderén C, Nordin A, Nordling E, Jensen AJ, Dahlgren C.

Biochem Pharmacol. 2011 Feb 1;81(3):402-11. doi: 10.1016/j.bcp.2010.11.005. Epub 2010 Nov 21.

PMID:
21095183
11.

3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.

Ranatunge RR, Earl RA, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schwalb DJ, Young DV, Zemtseva IS.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6049-52.

PMID:
15546727
12.

Leukotriene B4 (LTB4) receptor antagonists: a series of (hydroxyphenyl)pyrazoles.

Harper RW, Jackson WT, Froelich LL, Boyd RJ, Aldridge TE, Herron DK.

J Med Chem. 1994 Jul 22;37(15):2411-20.

PMID:
8057289
13.

Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.

Ioannidis S, Lamb ML, Davies AM, Almeida L, Su M, Bebernitz G, Ye M, Bell K, Alimzhanov M, Zinda M.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6524-8. doi: 10.1016/j.bmcl.2009.10.054. Epub 2009 Oct 24.

PMID:
19857966
14.

Identification of novel pyrrolopyrazoles as protein kinase C β II inhibitors.

Li H, Hong Y, Nukui S, Lou J, Johnson S, Scales S, Botrous I, Tompkins E, Yin C, Zhou R, He M, Jensen J, Bouzida D, Alton G, Lafontaine J, Grant S.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):584-7. doi: 10.1016/j.bmcl.2010.10.032. Epub 2010 Oct 13.

PMID:
21084194
15.

Discovery of a potent and selective series of pyrazole bacterial methionyl-tRNA synthetase inhibitors.

Finn J, Mattia K, Morytko M, Ram S, Yang Y, Wu X, Mak E, Gallant P, Keith D.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2231-4.

PMID:
12798340
16.

Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries.

Londregan AT, Piotrowski DW, Futatsugi K, Warmus JS, Boehm M, Carpino PA, Chin JE, Janssen AM, Roush NS, Buxton J, Hinchey T.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1407-11. doi: 10.1016/j.bmcl.2012.12.076. Epub 2013 Jan 5.

PMID:
23337601
17.

Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.

Hall A, Billinton A, Brown SH, Clayton NM, Chowdhury A, Giblin GM, Goldsmith P, Hayhow TG, Hurst DN, Kilford IR, Naylor A, Passingham B, Winyard L.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3392-9. doi: 10.1016/j.bmcl.2008.04.018. Epub 2008 Apr 11.

PMID:
18462938
18.

Pyrazole derived from (+)-3-carene; a novel potent, selective scaffold for sphingosine-1-phosphate (S1P(1)) receptor agonists.

Zécri FJ, Albert R, Landrum G, Hinterding K, Cooke NG, Guerini D, Streiff M, Bruns C, Nuesslein-Hildesheim B.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):35-7. doi: 10.1016/j.bmcl.2009.11.045. Epub 2009 Nov 15.

PMID:
19954976
19.

Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT.

Bioorg Med Chem. 2011 Jul 15;19(14):4173-82. doi: 10.1016/j.bmc.2011.06.016. Epub 2011 Jun 13.

PMID:
21708468
20.

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Quinn MT.

Mol Pharmacol. 2007 Apr;71(4):1061-74. Epub 2007 Jan 17.

Supplemental Content

Support Center